Related Experiment Video

Updated: Aug 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor

James R Tonra1, Dhanvanthri S Deevi, Erik Corcoran

  • 1ImClone Systems Inc., New York, New York, USA. James.Tonra@imclone.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 13, 2006
PubMed
Abstract

Insights

Combined therapy targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) showed synergistic antitumor effects in preclinical cancer models. This combination strategy holds significant therapeutic potential for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Combination therapies targeting both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways are under investigation for cancer treatment.
  • Synergistic interactions between therapeutic agents are crucial for maximizing antitumor effects.

Purpose of the Study:

  • To evaluate the synergistic interaction between the anti-EGFR antibody cetuximab and the anti-VEGFR2 antibody DC101.
  • To assess this combination in preclinical models of pancreatic (BxPC-3) and colon (GEO) cancer.

Main Methods:

  • In vivo isobologram analysis using a novel method to determine the combination index (CI), where CI < 1 indicates synergy.
  • Assessment of tumor cell proliferation, apoptosis, VEGF production, hypoxia, and tumor vascularization to elucidate the mechanistic basis of synergy.

Main Results:

  • Cetuximab and DC101 demonstrated synergistic antitumor effects in both BxPC-3 and GEO cancer models (CI = 0.1, P < 0.01).
  • Synergy is attributed to overlapping effects on tumor cells and vasculature, with potential molecular links involving VEGF production and hypoxia-inducible factor 1-alpha.

Conclusions:

  • Combined EGFR and VEGFR2 targeted therapy exhibits significant antitumor synergy.
  • This combination strategy presents considerable therapeutic potential for cancer treatment.

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...